Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study

International Journal of Cancer

Volumn 138, Issue 9, 2016, Pages 2161-2171

  Yuan, Jian Min ^a,b   Nelson, Heather H ^c,d   Butler, Lesley M ^a,b   Carmella, Steven G ^c   Wang, Renwei ^a   Kuriger Laber, Jacquelyn K ^c   Adams Haduch, Jennifer ^a   Hecht, Stephen S ^c   Gao, Yu Tang ^e   Murphy, Sharon E ^c,f  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chinese; CYP2A6; lung cancer; tobacco exposure biomarkers; total nicotine equivalents

Indexed keywords

3' HYDROXYCOTININE; COTININE; CYTOCHROME P450 2A6; NICOTINE; TOBACCO SMOKE; CYP2A6 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINA; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING HABIT; URINE LEVEL; ADVERSE EFFECTS; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; GENOTYPE; LUNG NEOPLASMS; METABOLISM; ODDS RATIO; POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHINA; COHORT STUDIES; COTININE; CYTOCHROME P-450 CYP2A6; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NICOTINE; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 84958891764     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29963     Document Type: Article

References (50)

1. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risk to humans, vol. 83. Lyon, France: IARC Scientific Publications, 2004. 36-40.
2. Brennan P, Hainaut P, Boffetta P., Genetics of lung-cancer susceptibility. Lancet Oncol 2011; 12: 399-408.
3. Hecht SS., Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res 2012; 14: 18-28.
4. Hecht SS., Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733-44.
5. International Agency for Research on Cancer. Smokeless tobacco and tobacco-specific nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 89. Lyon, France: IARC Scientific Publications, 2007. 421-583.
6. Yuan J-M, Koh WP, Murphy SE, et al., Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009; 69: 2990-5.
7. Yuan J-M, Gao YT, Murphy SE, et al., Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011; 71: 6749-57.
8. Jalas JR, Hecht SS, Murphy SE., Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005; 18: 95-110.
9. Dicke KE, Skrlin SM, Murphy SE., Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos 2005; 33: 1760-4.
10. Zhang X, D'Agostino J, Wu H, et al., CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther 2007; 323: 570-8.
11. Gervot L, Rochat B, Gautier JC, et al., Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 1999; 9: 295-306.
12. Hukkanen J, Jacob P, 3rd Benowitz NL,. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79-115.
13. von Weymarn LB, Brown KM, Murphy SE., Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J Pharmacol Exp Ther 2006; 316: 295-303.
14. Scherer G, Engl J, Urban M, et al., Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2007; 47: 171-83.
15. Fujieda M, Yamazaki H, Saito T, et al., Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25: 2451-8.
16. Wassenaar CA, Dong Q, Wei Q, et al., Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011; 103: 1342-6.
17. Wassenaar CA, Ye Y, Cai Q, et al., CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers-findings from two independent populations. Carcinogenesis 2015; 36: 99-103.
18. Loriot MA, Rebuissou S, Oscarson M, et al., Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001; 11: 39-44.
19. Tan W, Chen GF, Xing DY, et al., Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 2001; 95: 96-101.
20. Wang H, Tan W, Hao B, et al., Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003; 63: 8057-61.
21. Benowitz NL, Swan GE, Jacob P, et al., CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006; 80: 457-67.
22. Mwenifumbo JC, Tyndale RF., Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007; 8: 1385-402.
23. Derby KS, Cuthrell K, Caberto C, et al., Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 3526-35.
24. Yuan J-M, Ross RK, Wang XL, et al., Morbidity and mortality in relation to cigarette smoking in Shanghai, China. A prospective male cohort study. Jama 1996; 275: 1646-50.
25. Murphy SE, Park SS, Thompson EF, et al., Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups. Carcinogenesis 2014; 35: 2526-33.
26. Nakajima M, Fukami T, Yamanaka H, et al., Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006; 80: 282-97.
27. Bloom AJ, Harari O, Martinez M, et al., A compensatory effect upon splicing results in normal function of the CYP2A6 14 allele. Pharmacogenet Genomics 2013; 23: 107-16.
28. London SJ, Yuan J-M, Chung FL, et al., Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. Lancet 2000; 356: 724-9.
29. Hecht SS, Trushin N, Rigotty J, et al., Complete inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced rat lung tumorigenesis and favorable modification of biomarkers by phenethyl isothiocyanate. Cancer Epidemiol Biomarkers Prev 1996; 5: 645-52.
30. Benowitz NL., Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009; 49: 57-71.
31. Malaiyandi V, Lerman C, Benowitz NL, et al., Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006; 11: 400-9.
32. Carter B, Long T, Cinciripini P., A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res 2004; 6: 221-7.
33. Ho MK, Mwenifumbo JC, Al Koudsi N, et al., Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009; 85: 635-43.
34. Liu T, David SP, Tyndale RF, et al., Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 2011; 106: 985-94.
35. Bloom J, Hinrichs AL, Wang JC, et al., The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics 2011; 21: 403-16.
36. Miyamoto M, Umetsu Y, Dosaka-Akita H, et al., CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 1999; 261: 658-60.
37. Liu ZB, Shu J, Wang LP, et al., Cytochrome P450 2A6 deletion polymorphism and risk of lung cancer: a meta-analysis. Mol Biol Rep 2013; 40: 5255-9.
38. Liu T, Xie CB, Ma WJ, et al., Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. Environ Mol Mutagen 2013; 54: 133-40.
39. Liu YL, Xu Y, Li F, et al., CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. Tumour Biol 2013; 34: 2651-7.
40. Wang L, Zang W, Liu J, et al., Association of CYP2A6 4 with susceptibility of lung cancer: a meta-analysis. PLoS ONE 2013; 8: e59556
41. Amos CI, Wu X, Broderick P, et al., Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008; 40: 616-22.
42. Hung RJ, McKay JD, Gaborieau V, et al., A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633-7.
43. Thorgeirsson TE, Geller F, Sulem P, et al., A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452: 638-42.
44. McKay JD, Hung RJ, Gaborieau V, et al., Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008; 40: 1404-6.
45. Wang Y, Broderick P, Webb E, et al., Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008; 40: 1407-9.
46. Landi MT, Chatterjee N, Yu K, et al., A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 2009; 85: 679-91.
47. Truong T, Hung RJ, Amos CI, et al., Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst 2010; 102: 959-71.
48. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al., Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42: 448-53.
49. Loukola A, Buchwald J, Gupta R, et al., A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet 2015; 11: e1005498
50. Kumasaka N, Aoki M, Okada Y, et al., Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population. PLoS ONE 2012; 7: e44507